In fiscal year 2022, SAMJIN PHARMACEUTICAL (005500) reported revenue of 274.0 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2022 | 274.0 billion KRW | 23.2 billion KRW | 21.9 billion KRW | [source] |
| 2021 | 250.1 billion KRW | 33.9 billion KRW | 28.4 billion KRW | [source] |
| 2020 | 235.2 billion KRW | 32.2 billion KRW | 27.9 billion KRW | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2022 | 404.8 billion KRW | 130.2 billion KRW | 274.6 billion KRW | [source] |
| 2021 | 332.5 billion KRW | 98.3 billion KRW | 234.2 billion KRW | [source] |
| 2020 | — | — | — | — |
Cash Flow
| Year | Operating | Investing | Financing | Source |
|---|---|---|---|---|
| 2022 | 17.3 billion KRW | -70.1 billion KRW | 47.2 billion KRW | [source] |
| 2021 | — | — | — | [source] |
| 2020 | — | — | — | — |
Years without a source link are outside the DART financial API collection period.
Balance sheet figures for the relevant year were not collected.
Cash flow figures for the relevant year were not collected.